SEC Form 4
Heartflow, Inc. (HTFL) insider trading
In the 12 months to Oct 26, 2026, 7 HTFL insiders reported open-market sales of $140.0M across 31 filings; one director bought $1.1M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $140.0M
- 31 filings · 7 insiders
- Open-market purchases
- $1.1M
- 1 filing · Jeffrey C. Lightcap, Director
- Pre-arranged sales (10b5-1)
- 27 of 31
- $25.0M of $140.0M sold (18%)
Who traded HTFL, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
HTFL daily close from Oct 27, 2025 to Oct 26, 2026, between $20.49 and $56.71, last $56.64. 31 sale and 1 purchase filings by 8 insiders, marked at their filing dates. Bain Capital Life Sciences Fund III, L.P., 10% owner: sold $79.5M across 2 filings, first filed Feb 6, 2026, last Apr 30, 2026. BCLS Fund III Investments GP, LLC, 10% owner: sold $27.7M across 1 filing, first filed Apr 30, 2026, last Apr 30, 2026. John C.M. Farquhar, Chief Executive Officer: sold $12.9M across 14 filings, first filed Feb 10, 2026, last Oct 14, 2026. Bain Capital Life Sciences III General Partner, LLC, 10% owner: sold $7.8M across 1 filing, first filed Apr 30, 2026, last Apr 30, 2026. Campbell Rogers, Chief Medical Officer: sold $6.7M across 7 filings, first filed Feb 17, 2026, last Sep 21, 2026. Vikram Verghese, Chief Financial Officer: sold $5.0M across 4 filings, first filed Sep 4, 2026, last Sep 18, 2026. Jeffrey C. Lightcap, Director: bought $1.1M across 1 filing, first filed Dec 17, 2025, last Dec 17, 2025. Julie A. Cullivan, Director: sold $446.6K across 2 filings, first filed Feb 6, 2026, last Mar 6, 2026.
Largest mark · tap a row for others
Bain Capital Life Sciences Fund III, L.P. · 10% owner
Sale $56,100,000
2,000,000 shares at $28.05 avg
Filed Feb 6, 2026 · traded Feb 4
Close on filing date $27.74
Bain Capital Life Sciences Fund III, L.P. · 10% owner
10% owner
$79.5M soldBCLS Fund III Investments GP, LLC · 10% owner
10% owner
$27.7M soldJohn C.M. Farquhar · Chief Executive Officer
Chief Executive Officer
$12.9M soldBain Capital Life Sciences III General Partner, LLC · 10% owner
10% owner
$7.8M soldCampbell Rogers · Chief Medical Officer
Chief Medical Officer
$6.7M soldVikram Verghese · Chief Financial Officer
Chief Financial Officer
$5.0M soldJeffrey C. Lightcap · Director
Director
$1.1M boughtJulie A. Cullivan · Director
Director
$446.6K soldOpen-market trades
32 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Fund III, L.P. | 10% owner | $79.5M | — | 2 | — | |
| BCLS Fund III Investments GP, LLC | 10% owner | $27.7M | — | 1 | — | |
| John C.M. Farquhar | Chief Executive Officer | $12.9M | — | 14 | 100% of sales | |
| Bain Capital Life Sciences III General Partner, LLC | 10% owner | $7.8M | — | 1 | — | |
| Campbell Rogers | Chief Medical Officer | $6.7M | — | 7 | 100% of sales | |
| Vikram Verghese | Chief Financial Officer | $5.0M | — | 4 | 100% of sales | |
| Jeffrey C. Lightcap | Director | — | $1.1M | 1 | — | |
| Julie A. Cullivan | Director | $446.6K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 38,900 | $49.57 | $1.9M | 283,014 | |
traded | Campbell Rogers Chief Medical Officer | SalePre-arranged (10b5-1) | 19,682 | $50.15 | $987.1K | 79,956 | |
traded | Vikram Verghese Chief Financial Officer | SalePre-arranged (10b5-1) | 24,345 | $50.55 | $1.2M | 155,183 | |
traded | Vikram Verghese Chief Financial Officer | SalePre-arranged (10b5-1) | 34,975 | $50.08 | $1.8M | 179,528 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 38,900 | $46.78 | $1.8M | 321,914 | |
traded | Vikram Verghese Chief Financial Officer | SalePre-arranged (10b5-1) | 6,640 | $50.03 | $332.2K | 214,503 | |
traded | Vikram Verghese Chief Financial Officer | SalePre-arranged (10b5-1) | 33,416 | $49.85 | $1.7M | 221,143 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 27,230 | $50.00 | $1.4M | 360,814 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 32,676 | $45.00 | $1.5M | 388,044 | |
traded | Campbell Rogers Chief Medical Officer | SalePre-arranged (10b5-1) | 9,219 | $41.23 | $380.1K | 86,459 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 15,560 | $39.06 | $607.8K | 420,720 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 22,562 | $28.31 | $638.7K | 436,280 | |
traded | Campbell Rogers Chief Medical Officer | SalePre-arranged (10b5-1) | 9,219 | $25.72 | $237.1K | 88,731 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 22,562 | $27.75 | $626.1K | 435,373 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 38,900 | $35.00 | $1.4M | 457,935 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 22,562 | $28.50 | $643.0K | 496,835 | |
traded | Campbell Rogers Chief Medical Officer | SalePre-arranged (10b5-1) | 9,219 | $28.34 | $261.3K | 78,731 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 22,562 | $29.12 | $657.0K | 519,397 | |
traded | BCLS Fund III Investments GP, LLC 10% owner | Sale | 948,757 | $29.23 | $27.7M | 8,448,158 | |
traded | Bain Capital Life Sciences III General Partner, LLC 10% owner | Sale | 254,110 | $30.51 | $7.8M | 10,194,048 | |
traded | Bain Capital Life Sciences Fund III, L.P. 10% owner | Sale | 797,133 | $29.37 | $23.4M | 9,396,915 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 22,562 | $26.72 | $602.9K | 549,163 | |
traded | Campbell Rogers Chief Medical Officer | SalePre-arranged (10b5-1) | 64,533 | $24.64 | $1.6M | 81,002 | |
traded | Campbell Rogers Chief Medical Officer | SalePre-arranged (10b5-1) | 64,533 | $25.69 | $1.7M | 78,518 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 9,725 | $25.00 | $243.1K | 571,725 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 12,837 | $22.66 | $290.9K | 581,450 | |
traded | Julie A. Cullivan Director | SalePre-arranged (10b5-1) | 9,122 | $25.00 | $228.1K | 27,291 | |
traded | Campbell Rogers Chief Medical Officer | SalePre-arranged (10b5-1) | 65,153 | $24.49 | $1.6M | 76,034 | |
traded | John C.M. Farquhar Chief Executive Officer | SalePre-arranged (10b5-1) | 22,562 | $27.46 | $619.6K | 591,656 | |
traded | Bain Capital Life Sciences Fund III, L.P. 10% owner | Sale | 2,000,000 | $28.05 | $56.1M | 10,448,158 | |
traded | Julie A. Cullivan Director | SalePre-arranged (10b5-1) | 8,000 | $27.32 | $218.6K | 36,413 | |
traded | Jeffrey C. Lightcap Director | Purchase | 40,000 | $26.34 | $1.1M | 40,000 |
GET /stocks/filings/vX/form-4?tickers=HTFL&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"HTFL"
],
"issuer_cik": "0001464521",
"owner_cik": "0001900415",
"accession_number": "0001464521-26-000154",
"form_type": "4",
"filing_date": "2026-10-14",
"period_of_report": "2026-10-12",
"issuer_name": "Heartflow, Inc.",
"issuer_trading_symbol": "HTFL",
"owner_name": "Farquhar John C.M.",
"is_director": true,
"is_officer": true,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-12",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 38900,
"transaction_price_per_share": 49.568,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 283014,
"transaction_value": 1928195.2,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025."
},
{
"id": "F2",
"description": "This transaction was executed in multiple trades at price ranging from $49.52 to $50.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."
}
]
},
{
"tickers": [
"HTFL"
],
"issuer_cik": "0001464521",
"owner_cik": "0001585724",
"accession_number": "0001464521-26-000152",
"form_type": "4",
"filing_date": "2026-09-21",
"period_of_report": "2026-09-18",
"issuer_name": "Heartflow, Inc.",
"issuer_trading_symbol": "HTFL",
"owner_name": "Rogers Campbell",
"is_officer": true,
"officer_title": "Chief Medical Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-18",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 19682,
"transaction_price_per_share": 50.15,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 79956,
"transaction_value": 987052.2999999999,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F2",
"description": "Includes the sale of 6,503 shares of common stock held and the option exercise and sale of 13,179 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 61 records
- Option exercises28 records
- Tax withholding24 records
- Grants and awards7 records
- Other2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Heartflow, Inc.'s CEO sold stock?
Yes. John C.M. Farquhar (CEO) sold 350,100 shares ($12.9M) between Feb 2026 and Oct 2026, all under a pre-arranged 10b5-1 plan.
How current is HTFL’s insider data?
These are HTFL Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track HTFL insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for HTFL every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.